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Abstract
In the present study we evaluated the protection raised by immunization with recombinant influenza viruses carrying
sequences coding for polypeptides corresponding to medial and carboxi-terminal moieties of Trypanosoma cruzis
amastigote surface protein 2 (ASP2). Those viruses were used in sequential immunization with recombinant adenovirus
(heterologous prime-boost immunization protocol) encoding the complete sequence of ASP2 (Ad-ASP2) in two mouse
strains (C57BL/6 and C3H/He). The CD8 effector response elicited by this protocol was comparable to that observed in mice
immunized twice with Ad-ASP2 and more robust than that observed in mice that were immunized once with Ad-ASP2.
Whereas a single immunization with Ad-ASP2 sufficed to completely protect C57BL/6 mice, a higher survival rate was
observed in C3H/He mice that were primed with recombinant influenza virus and boosted with Ad-ASP2 after being
challenged with T. cruzi. Analyzing the phenotype of CD8+ T cells obtained from spleen of vaccinated C3H/He mice we
observed that heterologous prime-boost immunization protocol elicited more CD8+ T cells specific for the
immunodominant epitope as well as a higher number of CD8+ T cells producing TNF-a and IFN-c and a higher
mobilization of surface marker CD107a. Taken together, our results suggest that immunodominant subpopulations of CD8+
T elicited after immunization could be directly related to degree of protection achieved by different immunization protocols
using different viral vectors. Overall, these results demonstrated the usefulness of recombinant influenza viruses in
immunization protocols against Chagas Disease.
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Introduction
Over a hundred years after its first description, Chagas Disease
remains as an important public health problem, mostly in Latin
America. Nonetheless, the infection rate is increasing in other
continents, mostly by blood transfusion [1,2]. Accordingly to
WHO, there are currently over 10 million people infected in Latin
America and more than 100 million people live at risk areas in
endemic countries. Moreover, this disease kills approximately 13
thousand people every year, due to the clinical complications and
to the poor efficacy of the pharmacological treatment which is
highly toxic and effective mostly during the acute phase of disease
[3,4]. In addition, the resistance of parasites to chemotherapy is
another major drawback to the pharmacological treatment [5,6,7].
Thus, the development of vaccines is an important approach to be
used in therapy and prophylaxis of Chagas disease [3,8].
Many vaccination studies against Chagas’ disease already
provided evidence that CD8+ T cells play pivotal role on the
development of protective immunity [9,10,11,12]. Mechanisms
used by these cells to eliminate the parasite include directly killing
of infected cell or secretion of cytokines such as IFN-c [13,14].
Among the antigens that have been studied as potential candidates
for vaccine development, the surface amastigote protein 2 (ASP2)
has been found as one of the most promising [15,16]. In addition,
different strategies have already been tested to deliver this antigen
in mice, including the use of recombinant protein, plasmid DNA
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and recombinant viruses [17,18,19,20]. For instance, our group
demonstrated that two sequential immunizations with recombi-
nant HuA5 adenovirus encoding ASP2 were able to significantly
reduce the parasitemia and improve the survival of vaccinated
mice, when they were challenged with Y strain of T. cruzi [18].
However, in spite of these very promising results, a drawback in
use the same viral vector in sequential immunizations rely on the
risk that anti-vector antibodies generated after the priming could
neutralize the vector when it is used in further immunizations and,
consequently, hurdle the boost of heterospecific immune response
[21,22]. The limitation of anti-vector response elicited by
homologous prime-boost immunization could be surpassed by
different strategies, such as the use of two different recombinant
viruses on prime and boost immunizations [23,24].
Live recombinant influenza viruses have some features that
make them attractive to be used in vaccination protocols against
protozoan infections, as we can mention: They are well known
inductors of Cytotoxic T Lymphocytes (CTLs) by direct infection
of immature dendritic cells (DCs) and monocytes, facilitating
antigen (Ag) presentation both local and systemically [25,26,27]; It
is feasible to generate recombinant influenza viruses by reverse
genetics techniques [28]; There are different influenza A strains
and subtypes, which could be used in sequential immunizations to
overcome previous immune responses directed to the vector [29].
Therefore, in the present study we exploited the use of
recombinant influenza viruses carrying truncated sequences of
ASP2 in sequential immunization with adenovirus encoding
ASP2. This immunization protocol elicited potent anti-ASP2
cellular immune response, reduced the parasite burden and
improved the survival of vaccinated mice when they were
challenged with T. cruzi.
Materials and Methods
Mice and Ethics
Male of eight- to ten-weeks-old C57BL/6 and C3H/He mice
were obtained from Rene´ Rachou Research Institute’s (CPqRR)
animal facility center (Fiocruz, Belo Horizonte, Brazil) and housed
according to institutional standard guidelines. All animal studies
were approved by the Ethical Commission on Animals’ Use
(CEUA) at Oswaldo Cruz Foundation (Fiocruz), license LW-9-09,
and performed following institutional Guide for the Care and Use
of Laboratory Animals.
Cells and Parasites
MDCK and 293T cells (obtained from Pasteur Institut, FR)
were grown at 37uC under 5% CO2 in complete Dulbeccos
modified Eagle Medium (DMEM; SIGMA) with 1 mM sodium
pyruvate, 4.5 mg/ml L-glucose, 100 U/ml penicillin and 100 mg/
ml streptomycin (herein called complete DMEM medium) and
respectively supplemented with 5% or 10% heat inactivated fetal
calf serum (FCS; CULTILAB) [30]. Trypomastigotes from T. cruzi
Y Strain were maintained as previously described [17] and
challenge infections were performed by inoculating the mice with
1000 (C57BL/6) or 500 (C3H/He) bloodstream trypomastigotes
by intraperitoneal route. Mice survival was monitored daily and
parasite development was monitored by counting the number of
bloodstream trypomastigotes in 5 ml of fresh blood collected from
the tail vein [31].
Plasmids for Influenza Reverse Genetics
Wild type (pPRNA) and dicistronic (pPRNA38) plasmids from
neuraminidase (NA) segments of A/WSN/33 virus (H1N1) were
constructed as previously described [30,32,33]. Due the size
constraints, we constructed plasmids encoding 660 nucleotides
corresponding respectively to medial (M-ASP2) and carboxi-
terminal (C-ASP2) segments of ASP2 (figure 1A). These sequences
were obtained by PCR using the plasmid pAdCMV-ASP2 as
template [18] and specific primers for each ASP2 portion. The
amplicons were cloned into KpnI and NheI digested pIgSP plasmid
in frame to the sequence coding for k chain of mice immuno-
globulin that allows the secretion of the foreign sequence [17].
Those constructs were used as PCR templates to generate IgSP-M
or C-ASP2 segments which were site directed cloned into XhoI and
NheI digested pPRNA38 vector (Figure 1B). All primers sequences
are available under request and the respective presenting
haplotype were referenced within the correspondent portion
(Figure 1A) [34,35]. The generated plasmids (pPRNA38-M-
ASP2 and pPRNA38-C-ASP2) were analyzed using Dynamic
ET Dye Terminator Cycle Sequencing KITH (AMERSHAM) and
a Megabace 1000 automatic sequencer (AMERSHAM).
Influenza segments transfer plasmids pPOLI-HA, M, NS, PB2,
PB1, PA and NP and the expression plasmids pcDNA-PA, NP,
PB1 and PB2 were kindly provided by Dr George Brownlee (Sir
William Dunn School of Pathology, University of Oxford, Oxford,
United Kingdom) [36].
Generation of Recombinant Viruses
Recombinant adenovirus harboring the entire ASP2 coding
region (Ad-ASP2), recombinant adenovirus (Ad-CT) and influenza
(Flu-CT) virus, which encode unrelated sequences were generated
as previously described [18,30,37]. Recombinant influenza viruses
carrying dicistronic NA38-ASP2 segments were generated by the
twelve plasmid-driven genetic reverse technique, as described by
Fodor and co-workers with modifications [30,36]. Briefly, co-
cultures of HEK 293T and MDCK cells were simultaneously
transfected with plasmid coding the dicistronic NA segment
(pPRNA38-M-ASP2 or pPRNA38-C-ASP2; 0.5 mg), the expres-
sion plasmids (pcDNA-PB1, pcDNA-PB2, pcDNA-NP and
pcDNA-PA; 0.5 mg of each plasmid) and the other seven transfer
plasmids of influenza A/WSN/33 segments (0.5 mg of each
plasmid) using Fugene 6 ReagentH (ROCHE). Three days after
incubation, infectious viral particles of recombinant vNA38-M-
ASP2, vNA38-C-ASP2 (herein named respectively Flu-M-ASP2,
Flu-C-ASP2) were recovered, amplified, plaque purified and
titrated on MDCK as previously described [30].
Viral RNA Extraction, RT-PCR Analysis
Viral RNA (vRNA) extraction from cell-free supernatants of
infected MDCK cultures and RT-PCR analysis were performed as
previously described [33]. Amplicons were analyzed on 1%
agarose gel and visualized by ethidium bromide staining. RT-
PCR products were purified and presence of mutations was
determined by sequencing using Dynamic ET Dye Terminator
Cycle Sequencing KITH (AMERSHAM) and a Megabace 1000
automatic sequencer (AMERSHAM).
Peptides
Peptides VNHRFTLV and TEWETGQI were purchased from
Genscript (Piscataway, NJ). Peptide purity was in higher than
90%. Their identities were confirmed by Q-TOF Micro equipped
with an electrospray ionization source (Micromass, United
Kingdom).
ELISPOT and Intracellular Cytokine Staining
ELISPOT assay was performed essentially as previously
described [37]. Spleens cells of immunized mice were obtained
Recombinant Flu and Adenoviruses against T.Cruzi
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three weeks after boost immunization. They were treated with
ACK buffer for erythrocytes lysis and washed twice in RPMI
containing 5% FBS before to be resuspended in cell culture
medium consisting of RPMI 1640 medium (pH 7.4) supplemented
with 10 mM HEPES, 0.2% sodium bicarbonate, 59 mg of
penicillin/liter, 133 mg of streptomycin/liter, and 10% fetal
bovine serum (CULTILAB) containing recombinant IL-2
(100 U/ml). The viability of the cells was evaluated by using
0.2% trypan blue exclusion dye to discriminate between live and
dead cells. The number of spleen cells was adjusted to 16106 cells
per well in cell culture medium and stimulated with specific
peptides at final concentration of 10 mg/ml of VNHRFTLV (aa
553–560; for C57BL/6 splenocytes) or TEWETGQI (aa 320–327;
for C3H/He splenocytes). The spots were counted on a S5 Core
ELISPOT Analyser (CTL).
For Intracellular Cytokine Staining, the cell concentration was
adjusted to 16106 cells per well in cell culture medium containing
GolgiStop TM and GolgiPlugTM (according to manufacturer
instructions; BD Pharmingen) and -phycoerythrin (PE) anti-
CD107a (BD Pharmigen). In half of the cultures, a final
concentration of 10 mg/ml of VNHRFTLV (for C57BL/6
splenocytes) or TEWETGQI (for C3H/He splenocytes) peptide
was added. The cells were cultivated in U-bottom 96-well plates
(Corning) in a final volume of 200 ml at 37uC in a 5% CO2 humid
atmosphere. After 12 hour-incubation, cells were stained for
surface markers fluorescein isothiocyanate (FITC)-labeled dextra-
mer TEWETGQI (Immudex), after 10 minutes incubation, cells
were also stained with peridinin chlorophyll protein complex
(PerCP) anti-CD8, avidin-phycoerythrin (PeCy7) anti-CD8, or
FITC-labeled anti-CD3 (in samples without dextramer) antibodies
(BD Pharmigen). The cells were fixed and permeabilized using
Cytofix/Cytoperm kit (BD, Biosciences) according to manufac-
turer’s recommendations. Cells were then stained for intracellular
markers allophycocyanin (APC) anti-IFN-c, APC-Cy7 anti-TNF-
a, or PE Cy7 anti-TNF-a (BD Pharmigen). Finally, the cells were
fixed in 2% PBS-paraformaldehyde and at least 100,000 cells were
acquired on a FacsCanto, LSRFortessa or FacsAria II (BD,
Biosciences) flow cytometers and then analyzed with FlowJo
software (ThreeStar). The ancestry gates are represented in Figure
S1.
ELISA and Western Blot
Recombinant ASP2 (rASP2) protein was produced in Escherichia
coli as previously described [17]. The presence of sera specific anti-
ASP2 antibodies were assessed by enzyme-linked immunosorbent
assay (ELISA) on immunized mice sera obtained fourteen days
after the boost immunization. Briefly, plates (Maxisorb, NUNC)
were coated with 4 mg/mL (His65KDa, rASP2) and incubated at
4uC overnight. Mice sera were diluted 1:100 in blocking buffer
and incubated for 2 hours at 37uC. Plates were incubated with
peroxidase-conjugated goat anti-mouse IgG (SIGMA) one hour at
room temperature, and reactions were developed with 3,395,59-
tetrametylbenzidine (TMB) reagent (SIGMA) and read at 450 nm.
Alternatively, 0.5 mg of His65KDa, rASP2 were loaded on 12%
polyacrylamide gels and transferred to nitrocellulose membranes.
Membranes were then blocked and incubated with individual sera
of mice immunized with recombinant viruses. After extensive
washes, membranes were incubated with peroxidase-conjugated
Figure 1. Construction and characterization of recombinant influenza viruses. Schematic representation of primary sequence of
Amastigote Surface Protein 2 and its corresponding moieties, highlighting the mapped CD8 T cells epitopes (A). Schematic representation of the
neuraminidase dicistronic segment. NA38 segment contains an A/WSN/33 (WSN) derived recombinant neuraminidase (NA) segment followed by a
duplicated 39non coding (NC) sequence, XhoI and NheI cloning sites, a duplication of the last 42 nucleotides of NA (dark box) and the original 59NC
sequence (28 nucleotides). The foreign sequences (open boxes) were cloned between XhoI and NheI cloning sites (B).The plaque phenotype of the
wild type WSN and recombinant influenza viruses were assessed by standard agarose plaque assay in MDCK cells after 3 days of incubation at 35uC
and 5% CO2 (C).The NA segments of recombinant influenza viruses were analyzed by RT-PCR, using a set of primers that allows the amplification of
the region containing the inserted foreign sequence. Corresponding plasmids DNAs were amplified in parallel as positive control. The amplified
products were analyzes on a 1% agarose and visualized by ethidium bromide staining. The values depicted at the weight marker lane ar (D). W.M:
weight marker; M: medial moiety of ASP2, C: carboxi-terminal moiety of ASP2; b.p.: base pairs.
doi:10.1371/journal.pone.0061795.g001
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goat anti-mouse IgG (SIGMA) and detection was performed by
membrane exposure to X-ray films after a standard chemolumi-
niscent reaction (ECL Detection System, Amersham Biosciences).
To measure IFN-c production, spleen cells were obtained as
described above and incubated for 72 hours at 37uC, 5% CO2.
The IFN-c concentration was determined in cell culture superna-
tant with DuoSet ELISA Development System mouse IFN-c kit
(R&D Systems) according to manufacturer’s recommendations.
Immunizations
Heterologous prime-boost immunizations were performed as
previously described [30]. Briefly, the animals were lightly
anesthetized with a mixture of ketamine and xylazine and
inoculated by intranasal route (IN) with 103 plaque-forming unit
(pfu) of recombinant influenza viruses (Flu-CT or Flu-nASP2)
diluted in 25 ml of PBS. Four weeks later, the animals were
boosted with 56107 pfu of recombinant Ad-ASP2 or Ad-CT in
100 ml of PBS by subcutaneous route (SC). Alternatively, some
animals received two immunizations with 56107 pfu of recombi-
nant Ad-ASP2 or AdCT by SC route four weeks apart
(homologous prime-boost immunization protocol). Finally some
mice received only one immunization with 56107 pfu of
recombinant Ad-ASP2 by SC route.
Statistical Analysis
Data are expressed as 6 SEM and analyzed using GraphPad
Prism ver.5 Software. Statistic significance for ELISA, ELISPOT
and cytokine staining assays were evaluated using One-Way
ANOVA and non-parametric test followed by Bonferroni post-
test. Statistical significance for parasitemia was evaluated by 2-way
ANOVA with Bonferroni post-test. The Gehan-Breslow-Wilcoxon
test was performed to compare mouse survival curves.
Results
Generation and Characterization of Recombinant
Influenza Viruses
Recombinant influenza viruses harboring the medial or the
carboxi-terminal sequence of ASP-2 protein were recovered using
the 12 plasmid driven reverse genetics as previously described
[30]. These recombinant viruses, which were respectively named
Flu-M-ASP2 and Flu-C-ASP2, displayed lysis plaques in MDCK
cells similar in size than those found in cells infected with the
recombinant Flu-CT. In contrast, those viruses displayed lysis
plaques that were slightly smaller than those of the wild type WSN
virus (Figure 1C). In addition, their infectious titers (1.46106 pfu/
ml Flu-M-ASP2 and 2.86106 pfu/ml Flu-C-ASP2) were signifi-
cantly lower than those of WSN virus(16108 pfu/ml).
As shown in figure 1D, amplifications products of expected size
(,1000 bp) were found for each recombinant influenza virus
assayed. Moreover, when these amplicons were analyzed by
sequencing, we found no mutations, demonstrating that those
recombinant influenza viruses were genetically stable in cell
culture (data not shown).
Evaluation of Humoral Immune Response
Immunization protocols were carried out according to the
schedule depicted at figure 2A. Two weeks after the boost
immunization, specific anti-ASP2 IgG serum antibodies were
measured by ELISA and western blot, using the recombinant
ASP2 (His65KDa) protein as capture antigen. Western blot results
showed that specific anti-ASP2 IgG antibodies could be found in
sera of all C57BL/6 mice primed with Flu-C-ASP2 and boosted
with Ad-ASP2 (figure 2B), whereas only one animal that received a
single immunization with Ad-ASP2 displayed detectable levels of
specific anti-ASP2 antibodies. In addition, we detected higher
levels of specific anti-ASP2 antibodies in the sera of mice primed
with recombinant influenza than those found in animals that
received only one immunization with Ad-ASP2 (Figure 2C).
Interesting, neither by Western blot (data not shown) nor ELISA
(figure 2D), we were able to detect specific anti-ASP2 antibodies in
sera of C3H/He mice immunized with recombinant viruses,
irrespective the immunization protocol used in vaccination. It is
noteworthy that previous studies demonstrated that B epitopes are
located in C-terminal moiety of ASP-2 protein and humoral
immune response against intra-cellular amastigote proteins is not
essential for protection [34,38].
Specific Cellular Immune Response Against Protective
Epitopes
The activation of specific anti-ASP2 CD8+ T cell response was
evaluated in spleen of immunized mice by stimulating their
splenocytes with VNHRFTLV (H-2Kb-restricted, C57BL/6) or
TEWETGQI (H-2Kk-restricted, C3H) peptides, three weeks after
the boost immunization. As depicted in figure 3, specific IFN-c
producing CD8+ T cells could be found in spleen cells of mice
primed with Flu-C-ASP2 or Flu-M-ASP2 and boosted with Ad-
ASP2 (figure 3A and C). In addition, high amounts of IFN-c could
be measured in spleen cell culture supernatants stimulated ex-vivo
with their respective peptides (Figure 3B and D). Interesting, in
both cases, there was a clear improvement in the prime-boost
immunization, as we could find a significant increase in IFN-c
production on prime-boosted groups compared to single Ad-ASP2
immunized mice (Figure 3).
Protection Against Experimental Infection
The protection afforded by the vaccination protocols was
evaluated by challenging the vaccinated mice with 500 (C3H/He)
or 1000 (C57BL/6) bloodstream Y strain trypomastigotes.
Regarding the resistant mice strain, C57BL/6, a single immuni-
zation with Ad-ASP2 sufficed to reduce the parasitemia and to
completely protect the animals comparing to control immunized
groups (Figure 4A, p,0.05; and 4B, p,0.001).
Regarding the C3H/He mice, which display remarkable
susceptibility to T. cruzi, infection groups that received at least a
single immunization with recombinant adenovirus-ASP2 were
able to reduce the peak of parasitemia (Figure 4C, p,0.001),
control tissue pathology (Figure S2) and prolong survival
compared to the groups immunized with control recombinant
viruses (Figure 4D p,0.0005). Remarkably, a higher survival rate
was found in mice that were primed with Flu-M-ASP2 and
boosted with Ad-ASP2 as close to 80% of vaccinated mice
survived, comparing to mice that were primed with Flu-C-ASP2
and boosted with Ad-ASP2 (p= 0.0019). They also showed
significant improvement of survival when compared to single or
prime-boosted Ad-ASP2 immunized mice (p = 0.05, single and
0.08 homologous groups; Figure 4D).
In order to verify if the improvement of survival rate induced by
the Flu-Ad protocol could be due to recombinant influenza
properties, we tested the usefulness of a homologous intranasal
prime subcutaneous-boost immunization using Flu-M-ASP2 virus
in C3H/He mice strain. As demonstrated in Figure S3, we could
not observe the production of specific immune response under
stimulation neither by ELISPOT (Figure S3) nor intracellular
staining for IFN-c and TNF-a (data not shown) in splenocytes
derived from homologous immunized mice. This could be
expected since a single immunization with recombinant influenza
Recombinant Flu and Adenoviruses against T.Cruzi
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is known to elicit neutralizing antibodies that can prevent a proper
boost against the heterologous M-ASP2 polypeptide [30,32].
Cellular Immune Response Profile Elicited by Different
Immunization Protocols
The survival results found in C3H/He mice prompted us to
study more deeply the cellular immune profile elicited by the
immunization protocols. To this aim, C3H/He mice were
immunized as previously described and three weeks after the
boost immunization, spleen CD8+ T cells were evaluated for
intracellular staining of IFN-c and TNF-a cytokines and for the
surface mobilization of CD107a upon ex vivo stimulation with
peptide TEWETGQI, as described in Material and Methods
section. As depicted in figure 5A, the percentage of CD8+T cells
positive for at least one of the parameters evaluated were similar in
mice that received two immunizations with recombinant viruses,
irrespective the immunization strategy employed.
Regarding the phenotype of subpopulations of CD8+ T cells
found in vaccinated mice, triple (IFN-c, TNF-a, CD107a) and
double (IFN-c+CD107a+, and IFN-c+TNF-a) positive cells are
the major populations that were found after immunization with
recombinant viruses encoding ASP2 (Figure 5B). Interestingly,
mice immunized with recombinant viruses encoding ASP2
displayed similar percentage of CD8+ T cell subpopulations,
irrespective if they were immunized according to heterologous or
homologous immunization protocols, and similar to IFN-c
production seen by ELISPOT and ELISA, there was a clear
impact of boost immunization in the frequency of specific effector
CD8+ T cells comparing prime-boosted groups with Ad-ASP2
single immunized group (Figure 5A and 5B).
In order to perform a more accurate analysis on CD8+ T cells
elicited by immunization, we used a specific H-2Kd/TEWETGQI
dextramer. Mice were immunized as previously described and the
phenotype of specific CD8+ T cells was assessed in TEWETGQI
stimulated pooled spleen cells of vaccinated mice three weeks after
the last immunization. As depicted in figure 5C, mice vaccinated
with Flu-ASP2/Ad-ASP2 displayed the highest number of total
dextramer positive CD8+ T cells. The main subpopulation of
dextramer positive CD8+ T cells that were found in mice
immunized irrespective the tested protocols were triple positives
(IFN-c, TNF-a, CD107), followed by single (CD107+) positives
CD8+ T cells (Figure 5D). On the other hand, we could observe a
higher frequency of single IFN-c+TEWETGQI+ CD8+ T cells
(CD107a- TNF-a-) in heterologous (19%) and Ad-ASP2 single
(12.5%) immunized groups compared to Ad-ASP2/Ad-ASP2
group (2,9%).
Accordingly, Table 1 shows that besides heterologous Flu-Ad
immunization elicited higher numbers of CD8+TEWETGQI+ T
cells, also the frequency of CD8+TEWETGQI+ CD107a and/or
IFN-c and/or TNF-a positive cells increase above two fold
compared to homologous or single immunized groups. We could
also find a significant increase of perforin production under
stimulation only in the heterologous vaccinated group (Figure S4).
This results suggest the importance of those effector factors on
protection and could also indicate that the improvement of
survival by heterologous could be due to a higher number of
effector specific CD8+ T cells.
Figure 2. Immunization Schedule and Induction of specific anti-ASP2 humoral immune response in mice vaccinated with
recombinant viruses. Timeline representation of immunization schedule and experimental procedures (A). C57BL/6 mice were immunized as
described in Material and Methods. Two weeks after the boost immunization, the animals were bled and the presence of specific anti-ASP2 total IgG
antibodies in mice sera was evaluated by western by incubating individual (lanes 1–9) or pooled (lanes 10 and 11) sera of C57BL/6 mice with
nitrocellulose membranes loaded with recombinant ASP2 protein (His65KDa) as capture antigen blot (B). Alternatively, the antibodies levels were
measured by ELISA using individual sera of C5BL/6 (C) or C3H/He (D) mice sera diluted 1:100 and recombinant ASP2 protein as capture antigen.
Optical Density (OD) was measured at 450 nm.
doi:10.1371/journal.pone.0061795.g002
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Discussion
Recombinant viruses carrying foreign sequences have been
proven to be useful tools as vaccines against many pathogens,
including those which require the induction of potent type I T
cell immune responses, such as Leishmania s.p., Toxoplasma gondii
and Trypanosoma cruzi [39]. Studies carried out by our group
demonstrated that two immunizations with recombinant adeno-
virus carrying T. gondii or T. cruzi antigens were able to elicit
specific humoral and cellular immune response and to protect
different mouse lineages after challenge with those protozoan
parasites [18,37]. In spite of these very promising results, two
immunizations with recombinant adenovirus (homologous im-
munization protocol) raises some concerns, mostly due to the
elicited anti-vector immune response, which could hurdle the
immune response directed against the foreign sequence in
subsequent vaccinations. This problem could be surpassed by
using two different vectors for each immunization [24].
Therefore, we evaluated the use of recombinant influenza
viruses encoding ASP2 derived polypeptides as a tool for
priming the specific anti-ASP2 immune response, followed by
sequential immunization with a recombinant adenovirus encod-
ing ASP2. Regarding the naturally resistant C57BL/6 mice, the
prime with recombinant influenza virus encoding the carboxi-
terminal portion of ASP2 was as useful as recombinant
adenovirus in priming specific anti-ASP2 immune response.
Indeed, antibodies levels and the number IFN-c producers
CD8+ T cells specific for ASP2 were similar in mice primed
with recombinant influenza or adenovirus. Interesting, regarding
C57BL/6 mice strain, a single immunization with recombinant
adenovirus suffice to control parasitemia and to completely
protect the animals after challenge. Similar findings were
obtained by Duan and collaborators using recombinant Sendai
virus encoding ASP2, which was able to significantly reduce the
parasitemia and to completely protect C57BL/6 mice after the
challenge with Tulahuen strain [19].
Regarding the susceptible strain C3H/He, all immunizations
protocols employing Ad-ASP2 in our study were able to
significantly reduce the parasitemia, control at certain extent
tissue pathology and prolong survival of challenged animals.
Considering Y strain of Trypanosoma cruzi, there is a variable
correlation between blood parasitemia and survival rate, as
demonstrated in different mice strains [40,41]. However, we
could observe a correlation of parasitemia control with
prolonged survival in our model. Notwithstanding, an improve-
ment on the survival rate was observed in mice primed with
Figure 3. Cellular responses to immunodominant epitopes from ASP2 in mice immunized with recombinant viruses. C57BL/6 and
C3H/He mice were immunized as described in Material and Methods. Three weeks after the boost immunization, the presence of ASP-2 specific IFN-c
producing T cells in spleen cells of C57BL/6 (A) or C3H/He (B) mice were assessed by ELISPOT and culture supernatant ELISA (n = 8). To this aim, the
spleen cells of individual mice were stimulated 18 hours (ELISPOT) or 72 hours (ELISA) ex vivo with VNHRFTLV (aa 553–560; for C57BL/6) or TEWETGQI
(aa 320–327; for C3H/He) specific ASP2 peptides. Optical Density (OD) was measured at 450 nm.
doi:10.1371/journal.pone.0061795.g003
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recombinant influenza-M-ASP2 and boosted with recombinant
adenovirus even when compared to the survival of the animals
that were immunized once or twice with recombinant adeno-
virus, or primed using Flu-C-ASP2 which does not contain an
immunodominant epitope to C3H/He MHC-I haplotype.
These results seemed quite surprising because the specific anti-
ASP2 cellular immune response, measured by the number of
specific CD8+ T as well as by production of IFN-c was similar
in mice that were submitted either to the homologous or
heterologous prime and boost immunization protocols.
Phenotype analyses performed on total CD8+ T cells
obtained from vaccinated C3H/He showed that most effector
CD8+ T cells were polyfunctional and mostly triple (IFN-c,
TNF-a and CD107a) and double (IFN-c, CD107a) positives.
These results were similar to those obtained previously in
C57BL/6 mice that were immunized with naked DNA and
adenovirus encoding ASP2 [42]. Our results also showed that
mice that received one immunization with Ad-ASP2 displayed
similar CD8+ T cells phenotype than those observed in mice
that received two immunizations with recombinant viruses
encoding ASP2, suggesting that just one immunization with
Ad-ASP2 suffice for shaping the CD8+ T cells phenotype. Thus,
our observations indicate that a single immunization using Ad-
ASP2 suffice to stimulate a significant production of effector
cytokines IFN-c, TNF-a and mobilize CD107a, elicit an
immunodominant effector population which can control para-
sitemia, reduce tissue pathology and prolong survival when
compared to control immunized mice even in a susceptible
model. This is particularly important because often, studies
using different recombinant viruses or other vaccine vectors,
mice models and Trypanosoma cruzi strains without the single
immunized group could be overestimating their protection using
prime-boost protocols.
Remarkably, C3H/He mice that were primed with Flu-M-
ASP2 displayed higher number of dextramer positives CD8+ T
cells than mice that were immunized with Ad-ASP2. Moreover,
our results showed that a boost immunization with Ad-ASP2
did not augment the number of TEWETGQI dextramer
positive CD8+ T cells in mice primed with Ad-ASP2. To
discuss the reason by which the heterologous prime-boost
protocol could improve protection and enhance the frequency
of TEWETGQI CD8+ T cells we hypothesized that immuni-
zation with Flu-M-ASP2, which encodes only the medial moiety
of ASP2, primed the immunodominant CD8+ response towards
TEWETGQI epitope resulting in the expansion of this
population after boosting with Ad-ASP2. In contrast, priming
with Ad-ASP2, which carries the entire sequence of ASP2,
could possibly elicit immune response also against subdominant
epitopes of ASP2, resulting in a lower secondary response
against TEWETGQI immunodominant epitope after boost
[34,38,42,43,44]. Accordingly, previous results of our group
suggest that immunization with plasmids or adenovirus encoding
Figure 4. Parasitemia and survival curves of immunized mice challenged with T. cruzi. B6 and C3H/He mice were immunized as described
in Material and Methods. Four weeks after boost immunization, they were challenged intraperitoneally with 1000 and 500, respectively, T. cruzi Y
strain bloodstream trypomastigotes. Parasitemia was monitored on blood and depicted as the number of bloodstream trypomastigotes per milliliter
of blood (A, n = 4; C, n = 8). The survival of vaccinated C57BL/6 (B, n = 7) and C3H/He (D, n = 7–9) mice was followed during 50 days and showed as
Kaplan-Meier curves. * p,0.05, *** p,0.001.
doi:10.1371/journal.pone.0061795.g004
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Figure 5. Phenotype of anti-ASP2 specific CD8+ T cells elicited by vaccination with recombinant viruses. C3H/He mice were immunized
with recombinant viruses as described in Material and Methods. Two weeks after the last immunization, the spleen cells were harvested and
cultivated ex vivo with specific TEWETGQI CD8+ T peptide and incubated with anti-CD3, anti-CD8, permeabilized and fixed and stained with anti-
CD107a, anti-IFN-c and anti-TNF-a antibodies and assessed by flow cytometry. Percentage of effector CD8+ T cells reacting to the presence of
TEWETGQI peptide obtained from spleen cells of mice immunized with recombinant viruses (A). Percentage of CD8 T cells which produces IFN-c or/
and TNF-a or/and mobilizes the degranulation marker CD107a after stimulation with TEWETGQI (B), the statistics depicted are compared to groups of
mice immunized with control recombinant viruses. The number and frequency of dextramer positive CD8+ T found in 36104 CD8+ T (C). Functional
profile of CD8+ T cells subpopulations obtained from mice immunized with recombinant viruses (D). Response were depicted with different color
patterns according to the number of assessed functions (IFN-c, TNF-a and CD107a) displayed by each dextramer negative or dextramer positive CD8+
T cells subpopulations.
doi:10.1371/journal.pone.0061795.g005
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ASP2 subdominants epitopes afforded lower degree of protec-
tion when compared to that observed in animals immunized
with vectors encoding the immunodominant epitope [42]. A
reinforcement to this hypothesis could be found in the low
number of proteins encoded by influenza when compared to
adenovirus, which potentially reduces the number of viral
antigens that could compete with the heterologous antigen for
presentation by antigen-presenting cells [45,46]. The correlation
between TEWETGQI (present in medial portion of ASP2, M-
ASP2) immunodominant frequency and protection is reinforced
by the result of C3H/He mice that were immunized using
recombinant influenza encoding the C-terminus portion of
ASP2 as prime and Ad-ASP2 as boost presented a survival
curve similar to single immunized or homologous prime-boost
using Ad-ASP2 after infection (p = 0.46).
Another finding of our study was that the number of
dextramer stained CD8+ T cells producing IFN-c, TNF-a or
the surface marker CD107a found in animals primed with Flu-
M-ASP2 were approximately three times higher than those
observed in other vaccinated groups. However, while the role of
different T cell subpopulation to control the infection with some
viruses, bacteria and Plasmodium was already well documented
[47,48,49,50], the biological relevance of CD8+ T cells
subpopulations phenotypes to control the infection with T. cruzi
remains elusive [51]. The IFN-c production itself is known to
be important for protection against Trypanosoma cruzi infection in
many previous work of our and other groups [14,52,53,54,55].
On the other hand, other factors as the effector phenotype of
specific CD8+ T cells, the production of perforin, the re-
circulation of those cells out of spleen [56], their presence in the
heart [57,58], apoptosis of specific immunodominant anti-ASP2
CD8+ T cells [59], and the type of memory cells involved are
important to be considered [51]. Recently a group has elegantly
shown that multiple redundant effector CD8+ T cells factors
deriving from transferred Tc1 and Tc17 populations are
capable of protecting mice against viral infection [60], and as
CD8+ T cells have a major role in protection against
Trypanosoma cruzi infection, this statement is an interesting
subject of research. Thus, if the improvement of protection
observed in mice primed with recombinant influenza-M-ASP2
virus was only due to the higher number of CD8+T specific for
the immunodominant epitope or could also be due to other
factors remains to be solved.
In summary, we demonstrated that recombinant influenza
viruses encoding an ASP2 derived polypeptide would be useful
in heterologous prime-boost studies aiming the development of
vaccines against Chagas Disease. The priming with recombinant
influenza virus followed by boost with recombinant adenovirus
could properly augment the number of effector CD8+ T cells
specific for ASP2 immunodominant epitope, whose displayed
unique phenotype and resulted in increased survival of
vaccinated C3H/He mice challenged with T. cruzi.
Supporting Information
Figure S1 Representative of ancestry gates for flow
cytometry experiments. Correspondent ancestry gates for the
figure 5 analysis.
(TIF)
Figure S2 Histopathological analyses of liver, spleen
and heart derived from infected mice. Male C3H/He mice
were primed and boosted according different immunization
protocols and infected with 500 bloodstream trypomastigotes of
Y strain of T. cruzi. Fifteen days after the infection, mice were
euthanized and spleen, liver and heart were harvested, fixed and
processed for histopathology. The organ sections were stained
using hematoxilin-eosin and the degree of tissue inflammation was
evaluated (scale bar - 100 mm).
(TIF)
Figure S3 Cellular responses to immunodominant
epitope from ASP2 in mice immunized twice using Flu-
M-ASP2. ELISPOT of stimulated splenocytes taken from C3H/
He mice immunized with the depicted protocols. The prime-boost
was performed within an interval of 28 days and the experiment
was performed 21 days post boost. The splenocytes were
incubated 18 h in the presence of 10 mg of TEWETGQI peptide
(n = 5 for all groups except non-immunized group NI/NI, n= 3).
(TIF)
Figure S4 Perforin production in splenocytes derived
from C3H/He immunized mice. Splenocytes derived from
immunized C3H/He mice were ex vivo stimulated or not in the
presence of Brefeldin A and Monesin A and the immunodominant
peptide TEWETGQI for 12 hours, prepared, labeled and
submitted to flow cytometry (n = 4). N.I. Non-immunized/Non-
infected. Their staining profiles were analyzed using FlowJo and
statistical analysis performed was 2-Way ANOVA with Bonferroni
post-test using GraphPad Prism 5.0 Software.
(TIF)
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